Prognostic and Predictive Factors and Targets for Therapy in Breast Cancer

[1]  J. Klijn.  Herceptin in single and combined treatment modalities in pretreated patients with metastatic breast cancer: the Dutch experience , 2002 .

[2]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[3]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[4]  T. Sellers,et al.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.

[5]  J. Klijn,et al.  Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. , 2001, European journal of cancer.

[6]  D. Berry,et al.  Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  J. Foekens,et al.  Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features , 2001, British Journal of Cancer.

[8]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[9]  T. H. van der Kwast,et al.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.

[10]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[11]  P. Schein.  The case for a new national program for the development of cancer therapeutics. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Bundred,et al.  Prognostic and predictive factors in breast cancer. , 2001, Cancer treatment reviews.

[13]  I. Diel.  Prognostic factors for skeletal relapse in breast cancer. , 2001, Cancer treatment reviews.

[14]  G. Riggins,et al.  Gene discovery using the serial analysis of gene expression technique: implications for cancer research. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K S Panageas,et al.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[18]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[19]  F. Brunicardi,et al.  Treatment of Metastatic Breast Cancer With Somatostatin Analogues—A Meta-Analysis , 2001, Annals of Surgical Oncology.

[20]  I. Ellis,et al.  Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  E. Eisenhauer.  From the molecule to the clinic--inhibiting HER2 to treat breast cancer. , 2001, The New England journal of medicine.

[22]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[23]  T. Aas,et al.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. , 2001, Cancer research.

[24]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[25]  D. Visscher,et al.  Centrally Necrotizing Carcinomas of the Breast: A Distinct Histologic Subtype With Aggressive Clinical Behavior , 2001, The American journal of surgical pathology.

[26]  M. Hidalgo,et al.  Matrix metalloproteinase inhibitors: how can we optimize their development? , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R Yancik,et al.  Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.

[28]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[29]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[30]  F. Collins,et al.  Implications of the Human Genome Project for medical science. , 2001, JAMA.

[31]  J. Foekens,et al.  Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. , 2001, Cancer research.

[32]  C. Isaacs,et al.  New prognostic factors for breast cancer recurrence. , 2001, Seminars in oncology.

[33]  R. Blamey,et al.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Olsen,et al.  Prognosis of cancers associated with venous thromboembolism. , 2000, The New England journal of medicine.

[35]  M. Pagano,et al.  The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer , 2000, Breast Cancer Research.

[36]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[37]  B. Trock,et al.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.

[38]  E. Sausville,et al.  Molecules for the millennium: how will they look? New drug discovery year 2000 , 2000, British Journal of Cancer.

[39]  C. Rinker-Schaeffer,et al.  Metastasis-suppressor genes: a review and perspective on an emerging field. , 2000, Journal of the National Cancer Institute.

[40]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[41]  J. Foekens,et al.  Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer , 2000, Steroids.

[42]  K. Keyomarsi,et al.  Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. , 2000, Journal of the National Cancer Institute.

[43]  Ester Piek,et al.  Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .

[44]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[45]  C. Seynaeve,et al.  Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer , 2000, British Journal of Cancer.

[46]  P. Devilee,et al.  Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation , 2000, The Lancet.

[47]  J. Klijn,et al.  Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. , 2000, Journal of the National Cancer Institute.

[48]  M. Piccart,et al.  The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  R. Gelber,et al.  Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.

[50]  R. Vossen,et al.  Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.

[51]  R. Elledge,et al.  Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.

[52]  V. Speirs,et al.  Prognostic significance of oestrogen receptor β in breast cancer , 2000 .

[53]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[54]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[55]  G. Bastert,et al.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.

[56]  T. Powles,et al.  Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[58]  J. Foekens,et al.  Bcar1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment. , 2000, Journal of the National Cancer Institute.

[59]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  G. Davey Smith,et al.  Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? , 1999, The Journal of endocrinology.

[61]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[62]  J. Foekens,et al.  Prognostic value of CD44 variant expression in primary breast cancer , 1999, International journal of cancer.

[63]  T. Key,et al.  Serum oestradiol and breast cancer risk. , 1999, Endocrine-related cancer.

[64]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[65]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  John Calvin Reed,et al.  Prognostic significance of apoptosis regulators in breast cancer. , 1999, Endocrine-related cancer.

[67]  J. Foekens,et al.  Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer , 1999, British Journal of Cancer.

[68]  J. Foekens,et al.  Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[70]  S. Bull,et al.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Foekens,et al.  Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. , 1998, British Journal of Cancer.

[72]  B. Trock,et al.  Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  J. Foekens,et al.  Prognostic significance of cathepsins B and L in primary human breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Foekens,et al.  Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer , 1998, Breast Cancer Research and Treatment.

[75]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[76]  J. Foekens,et al.  The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. , 1997, British Journal of Cancer.

[77]  H. Dotzlaq.  Expression of Estrogen Receptor- in Human Breast Tumors , 1997 .

[78]  J. Foekens,et al.  Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols. , 1997, Anticancer research.

[79]  R. Gelman,et al.  Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Foekens,et al.  Multidrug resistance protein in recurrent breast cancer , 1997, The Lancet.

[81]  A. Harris.  Antiangiogenesis for cancer therapy , 1997, The Lancet.

[82]  J. Foekens,et al.  DNA‐synthesis enzyme activity: A biological tool useful for predicting anti‐metabolic drug sensitivity in breast cancer? , 1997, International journal of cancer.

[83]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  T. H. van der Kwast,et al.  The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. , 1996, European journal of cancer.

[85]  J. Foekens,et al.  TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients , 1996, Genes, chromosomes & cancer.

[86]  J. Moormeier.  Breast Cancer in Black Women , 1996, Annals of Internal Medicine.

[87]  M. Fernö,et al.  Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. , 1996, European journal of cancer.

[88]  J. Foekens,et al.  Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysis , 1996, International journal of cancer.

[89]  R. Dickson,et al.  Growth factors in breast cancer. , 1995, Endocrine reviews.

[90]  N. Brünner,et al.  Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  J. Foekens,et al.  Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. , 1995, British Journal of Cancer.

[92]  J. Foekens,et al.  Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.

[93]  M. Duffy,et al.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer , 1995, International journal of cancer.

[94]  J. Foekens,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.

[95]  J. Foekens,et al.  Association between rb‐1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival , 1995, International journal of cancer.

[96]  J. Foekens,et al.  Expression of tumor‐associated 90k‐antigen in human breast cancer: No correlation with prognosis and response to first‐line therapy with tamoxifen , 1995, International journal of cancer.

[97]  J. Foekens,et al.  Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. , 1995, Cancer research.

[98]  U. Veronesi,et al.  Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  J. Foekens,et al.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. , 1994, British Journal of Cancer.

[100]  W. Kuo,et al.  Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. , 1994, Cancer research.

[101]  J. Foekens,et al.  Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients. , 1994, British Journal of Cancer.

[102]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  F. Spyratos,et al.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. , 1994, British Journal of Cancer.

[105]  Teri Oldaker,et al.  DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients , 1993, Breast Cancer Research and Treatment.

[106]  T. Powles,et al.  The prognostic significance of transforming growth factors in human breast cancer. , 1993, British Journal of Cancer.

[107]  J. Foekens,et al.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[109]  J. Foekens,et al.  Cell biological factors associated with the response of breast cancer to systemic treatment. , 1993, Cancer treatment reviews.

[110]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[111]  J. Foekens,et al.  Clinical breast cancer, new developments in selection and endocrine treatment of patients , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[112]  J. Foekens,et al.  Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[113]  F. Spyratos,et al.  Multiparametric prognostic evaluation of biological factors in primary breast cancer. , 1992, Journal of the National Cancer Institute.

[114]  Simpson Jf,et al.  Prognostic value of histopathology in the breast. , 1992 .

[115]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[116]  J. Foekens,et al.  Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. , 1992, Cancer research.

[117]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[118]  J. Cairns,et al.  Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. , 1992, British Journal of Cancer.

[119]  J. Foekens,et al.  Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. , 1992, European journal of cancer.

[120]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[121]  C. Steel,et al.  Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. , 1991, British Journal of Cancer.

[122]  A. Harris,et al.  Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[123]  J. Foekens,et al.  Prediction of relapse and survival in breast cancer patients by pS2 protein status. , 1990, Cancer research.

[124]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[125]  K. Ulm,et al.  Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .

[126]  J. Foekens,et al.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.

[127]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[128]  J. Foekens,et al.  Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. , 1989, Endocrinology.

[129]  J. Klijn,et al.  Antiprogestins, a new form of endocrine therapy for human breast cancer. , 1989, Cancer research.

[130]  J. Foekens,et al.  Insulin‐like growth factor‐1 receptors and insulin‐like growth factor‐1‐like activity in human primary breast cancer , 1989, Cancer.

[131]  R. Coombes,et al.  POSSIBLE ROLE FOR VITAMIN D IN CONTROLLING BREAST CANCER CELL PROLIFERATION , 1989, The Lancet.

[132]  J. Bonneterre,et al.  Presence and characterization of insulin-like growth factor 1 receptors in human benign breast disease. , 1988, European journal of cancer & clinical oncology.

[133]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[134]  C. Redmond,et al.  Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  J. Klijn,et al.  The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer , 1988, Cancer.

[136]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[137]  J. Foekens,et al.  Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. , 1987, Cancer research.

[138]  E. Jensen.  Hormone dependency of breast cancer , 1981, Cancer.

[139]  H. Portengen,et al.  Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. , 1980, Cancer research.

[140]  Langlands Ao,et al.  Prognosis in breast cancer: the effect of age and menstrual status. , 1979 .

[141]  J. Foekens,et al.  The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study , 2004, Breast Cancer Research and Treatment.

[142]  G. Bastert,et al.  Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters , 2004, Breast Cancer Research and Treatment.

[143]  I. Ellis,et al.  Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer , 2004, Breast Cancer Research and Treatment.

[144]  Z. Bebők,et al.  Prognostic relevance of transforming growth factor alpha (TGF-α) and tumor necrosis factor alpha (TNF-α) detected in breast cancer tissues by immunohistochemistry , 2004, Breast Cancer Research and Treatment.

[145]  P. Steeg,et al.  Nm23 and breast cancer metastasis , 2004, Breast Cancer Research and Treatment.

[146]  S. Johnston,et al.  Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. , 2001, The Lancet. Oncology.

[147]  M. Eichelbaum,et al.  Microsomal epoxide hydrolase expression as a predictor of tamoxifen response in primary breast cancer: a retrospective exploratory study with long-term follow-up. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  J. Arends,et al.  pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer. , 1998, Anticancer research.

[149]  J. Foekens,et al.  Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. , 1998, British Journal of Cancer.

[150]  J. Foekens,et al.  p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  S. Martino,et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[152]  N. Janin,et al.  Should prophylactic surgery be used in women with a high risk of breast cancer? , 1997, European journal of cancer.

[153]  Helena R. Chang,et al.  Younger women with breast carcinoma have a poorer prognosis than older women , 1996, Cancer.

[154]  E. Oldfield,et al.  Heterogeneity of subcellular localization of p53 protein in human glioblastomas. , 1994, Cancer research.

[155]  J. Foekens,et al.  Prognostic factors and response to therapy in breast cancer. , 1993, Cancer surveys.

[156]  I. Christensen,et al.  Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. , 1993, European journal of cancer.

[157]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[158]  J. Baak,et al.  The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. , 1989, Cytometry.

[159]  G M Clark,et al.  Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  R. Bain,et al.  Racial differences in survival of women with breast cancer. , 1986, Journal of chronic diseases.

[161]  K. Horwitz,et al.  Progestin action and progesterone receptor structure in human breast cancer: a review. , 1985, Recent progress in hormone research.